QUINCE THERAPEUTICS INC (QNCX) Stock News
NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD
QNCX Latest News, Press Relases and Analysis
Top movers in Wednesday's after hours session
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
Wall Street wrapped up the week with a bang, as a solid jobs report and a possible thaw in US-China trade tensions gave investors plenty to cheer about. The S&P 500 notched its longest bull run in nearly two decades, surging for a ninth consecutive day and fully erasing the losses triggered by President Trump’s early-April ‘Liberation Day’ tariff blitz. Watching the current situation from Oppenheimer, chief investment strategist John Stoltzfus believes that the markets are finally finding their
Quince Therapeutics to Present at Citizens Life Sciences Conference
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics to Participate at Upcoming Investor Conferences
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
Quince Therapeutics just reported results for the second quarter of 2024.
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Quince Therapeutics (NASDAQ:QNCX) just reported results for the second quarter ...
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
Quince Therapeutics just reported results for the first quarter of 2024.
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
Quince Therapeutics just reported results for the fourth quarter of 2023.